A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.

INTRODUCTION: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the virus responsible for COVID-19. It is one of the most mutating virus in the world. These mutations are responsible for the appearance of new variants, the most recent of which is Omicron (line B.1.1.529). This new vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Minka, S.O, Minka, F.H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Immunological Societies. Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815275/
https://www.ncbi.nlm.nih.gov/pubmed/35131373
http://dx.doi.org/10.1016/j.imlet.2022.02.002
_version_ 1784645248927924224
author Minka, S.O
Minka, F.H
author_facet Minka, S.O
Minka, F.H
author_sort Minka, S.O
collection PubMed
description INTRODUCTION: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the virus responsible for COVID-19. It is one of the most mutating virus in the world. These mutations are responsible for the appearance of new variants, the most recent of which is Omicron (line B.1.1.529). This new variant was first identified in South Africa in November 2021. The main fear with this variant is that of an immune escape and ineffectiveness of vaccines currently available. OBJECTIVE: We studied the response of our immune system and the effectiveness of current vaccines against SARS-CoV-2 Omicron VOC. METHODS: We carried out a narrative review from 32 scientific articles from databases: MEDLINE (PubMed), Embase, BioRxiv and MedRxiv. RESULTS: Faced with SARS-CoV-2 Omicron VOC: The humoral immune response decreased, while the cellular immune response was preserved. The booster vaccine provided protection against symptomatic or non-symptomatic infections, transmission, and serious forms. CONCLUSION: In the end, according to these data, the 3rd dose appears to be the solution to be able to defeat SARS-CoV-2 Omicron VOC. But the health authorities must not forget to insist on the primary vaccination of individuals not yet vaccinated, as well as on an "equal" distribution of vaccines against COVID-19 throughout the world.
format Online
Article
Text
id pubmed-8815275
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Federation of Immunological Societies. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-88152752022-02-04 A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant. Minka, S.O Minka, F.H Immunol Lett Article INTRODUCTION: SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the virus responsible for COVID-19. It is one of the most mutating virus in the world. These mutations are responsible for the appearance of new variants, the most recent of which is Omicron (line B.1.1.529). This new variant was first identified in South Africa in November 2021. The main fear with this variant is that of an immune escape and ineffectiveness of vaccines currently available. OBJECTIVE: We studied the response of our immune system and the effectiveness of current vaccines against SARS-CoV-2 Omicron VOC. METHODS: We carried out a narrative review from 32 scientific articles from databases: MEDLINE (PubMed), Embase, BioRxiv and MedRxiv. RESULTS: Faced with SARS-CoV-2 Omicron VOC: The humoral immune response decreased, while the cellular immune response was preserved. The booster vaccine provided protection against symptomatic or non-symptomatic infections, transmission, and serious forms. CONCLUSION: In the end, according to these data, the 3rd dose appears to be the solution to be able to defeat SARS-CoV-2 Omicron VOC. But the health authorities must not forget to insist on the primary vaccination of individuals not yet vaccinated, as well as on an "equal" distribution of vaccines against COVID-19 throughout the world. European Federation of Immunological Societies. Published by Elsevier B.V. 2022-03 2022-02-04 /pmc/articles/PMC8815275/ /pubmed/35131373 http://dx.doi.org/10.1016/j.imlet.2022.02.002 Text en © 2022 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Minka, S.O
Minka, F.H
A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
title A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
title_full A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
title_fullStr A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
title_full_unstemmed A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
title_short A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.
title_sort tabulated summary of the evidence on humoral and cellular responses to the sars-cov-2 omicron voc, as well as vaccine efficacy against this variant.
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815275/
https://www.ncbi.nlm.nih.gov/pubmed/35131373
http://dx.doi.org/10.1016/j.imlet.2022.02.002
work_keys_str_mv AT minkaso atabulatedsummaryoftheevidenceonhumoralandcellularresponsestothesarscov2omicronvocaswellasvaccineefficacyagainstthisvariant
AT minkafh atabulatedsummaryoftheevidenceonhumoralandcellularresponsestothesarscov2omicronvocaswellasvaccineefficacyagainstthisvariant
AT minkaso tabulatedsummaryoftheevidenceonhumoralandcellularresponsestothesarscov2omicronvocaswellasvaccineefficacyagainstthisvariant
AT minkafh tabulatedsummaryoftheevidenceonhumoralandcellularresponsestothesarscov2omicronvocaswellasvaccineefficacyagainstthisvariant

Ejemplares similares